Filter by Interests
Filter by ContentType
Looking to a future of multiplex cell engineering
Marco Alessandrini
11 January 2024
Interview
Exploring the burgeoning role of non-viral approaches in the delivery of nucleic acids
Zhenghong Gao
05 January 2024
Interview
Advancing multiplex base editing into the clinic
Gopi Shanker
10 November 2023
Interview
Exploring the convergence of gene editing and RNAi in iPSC-derived allogeneic cell therapy
Vlad Seitan
08 November 2023
Interview
Developing a multiplex gene editing approach targeting viral infection
TJ Cradick
08 November 2023
Interview
Bringing the Sleeping Beauty transposon system to the clinic
Zoltán Ivics
18 October 2023
Interview
Developing universal AAV immuno-gene therapy for oncology
Nicole Paulk
24 August 2023
Interview
Does synthetic biology hold the key to unlocking solid tumors for cell and gene therapy?
Ming-Ru Wu
21 August 2023
Interview
Rearming the immune system with personalized allogeneic CAR-T cell therapy
Olivier Negre
18 August 2023
Interview
Exploring current shortfalls and potential improvements for non-viral gene delivery in cystic fibrosis
Uta Griesenbach
05 August 2023
Interview
Developing non-viral delivery & cell engineering technologies for ex vivo T cell immunotherapies
Julie Shi, Nirveek Bhattacharjee
30 June 2023
Interview
Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)
Adrian Bot
28 June 2023
Interview
At the cutting edge of AAV capsid engineering
Eric Kelsic, Adrian Veres
31 May 2023
Interview
Utilizing AI to drive AAV-based gene delivery to the CNS
David Huss
31 May 2023
Interview
Assessing recent milestones in AAV capsid discovery & development for CNS applications
Mathieu Nonnenmacher
09 May 2023
Interview
Leveraging derisked AAV vector development & delivery approaches to enhance speed to market for rare disease gene therapies
Adrien Lemoine
28 April 2023
Interview
Navigating the path to clinic for ATMPs: a regulator’s perspective
James W McBlane
02 February 2023
Interview
Leveraging cellular immunotherapy at the cutting edge of autoimmune disease R&D
Silvio Manfredo-Vieira
12 December 2022
Interview
Advancing genome edited allogeneic cell therapies into the clinic
Steve Kanner
26 August 2022
Interview
Ensuring commercial readiness in the cellular cancer immunotherapy space
Julian Adams, Michele Korfin, Ronit Simantov
16 August 2022
Interview
Driving stem cell innovation
Brock Reeve
27 May 2022
Interview